Impact of Human Immunodeficiency Virus Type 1 Subtype C on Drug Resistance Mutations in Patients from Botswana Failing a Nelfinavir-Containing Regimen-Reference-Cited by-同舟云学术

Impact of Human Immunodeficiency Virus Type 1 Subtype C on Drug Resistance Mutations in Patients from Botswana Failing a Nelfinavir-Containing Regimen

Published:2006-06 Issue:6 Volume:50 Page:2210-2213
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Doualla-Bell Florence¹²,Avalos Ava¹³,Gaolathe Tendani¹³,Mine Madisa¹³,Gaseitsiwe Simani¹,Ndwapi Ndwapi¹³,Novitsky Vladimir A.⁴,Brenner Bluma²,Oliveira Maureen²,Moisi Daniella²,Moffat Howard³,Thior Ibou¹,Essex Max⁴,Wainberg Mark A.²

Affiliation:

1. Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana

2. McGill University AIDS Centre, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada

3. Infectious Disease Care Clinic, Princess Marina Hospital, Gaborone, Botswana

4. Harvard School of Public Health, Boston, Massachusetts

Abstract

ABSTRACT Among 16 human immunodeficiency virus-infected (subtype C) Batswana patients who failed nelfinavir (NFV)-containing regimens, the most prevalent mutation observed was D30N (54%), followed by L90M (31%). L89I, K20T/I, and E35D polymorphic changes were also identified. These findings suggest that subtype C viruses in Botswana may develop resistance to NFV via subtype-specific pathways.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01447-05

Reference18 articles.

1. Brenner, B., D. Turner, M. Oliveira, D. Moisi, M. Detorio, M. Carobene, R. G. Marlink, J. Schapiro, M. Roger, and M. A. Wainberg. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to nonnucleoside reverse transcriptase inhibitors. AIDS17:F1-F5.

2. The M184V Substitution in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Delays the Development of Resistance to Amprenavir and Efavirenz in Subtype B and C Clinical Isolates

3. Doualla-Bell, F., A. Avalos, T. Gaolathe, M. Mine, S. Gaseitsiwe, B. Brenner, N. Ndwapi, H. Moffat, I. Thior, M. Essex, and M. A. Wainberg. 2005. Frequency and patterns of specific PR mutations in Batswana subtype C patients who failed a nelfinavir-containing HAART regimen. XIV International HIV Drug Resistance Workshop, June 7-11, 2005. Antivir. Ther.10:S150.

4. Doualla-Bell, F., S. Gaseitsiwe, T. Ndungu, M. Modukanele, T. Peter, V. A. Novitsky, N. Ndwapi, G. Tendani, A. Avalos, W. Wester, H. Bussmann, P. Cardiello, R. Marlink, H. Moffat, I. Thior, M. A. Wainberg, and M. Essex. 2004. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir. Chem. Chemother.15:189-200.

5. Frater, J. 2002. The impact of HIV-1 subtype on the clinical response on HAART. J. HIV Ther.7:92-96.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Associations of Mutations within the HIV-1 Env and Gag Genes Conferring Protease Inhibitor (PI) Drug Resistance;Microbiology Research;2021-12-15

2. Reaching 90–90–90 in Botswana;Current Opinion in HIV and AIDS;2019-11

3. Subtype-Specific Analysis of the K65R Substitution in HIV-1 That Confers Hypersusceptibility to a Novel Nucleotide-Competing Reverse Transcriptase Inhibitor;Antimicrobial Agents and Chemotherapy;2015-03-16

4. HIV-1 Genetic Variability and Clinical Implications;ISRN Microbiology;2013-06-17

5. The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs;Molecular Biology International;2012-06-26